Sphera Funds Management’s aTyr Pharma ATYR Stock Holding History

Sphera Funds Management’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-2,604	Closed	-$358K	–	123
2015 Q4	$358K	Sell	2,604 -12,327	-83%	-$1.75M	0.05%	115
2015 Q3	$2.15M	Hold	14,931	–	–	0.27%	87
2015 Q2	$3.7M	Buy	+14,931	New	+$4.64M	0.36%	66

Other funds holding ATYR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

GCM

Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

TAM

Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return

Sphera Funds Management's ATYR Position: Q1 2016 in Review

Sphera Funds Management sold out of aTyr Pharma (ATYR) in Q1 2016, closing a stake of 2,604 shares — an estimated $358K sold.

Sphera Funds Management first reported a position in ATYR in Q2 2015 and held it in 3 quarters. The position peaked at $3.7M in Q2 2015. 50 funds tracked by Wall St. Rank hold ATYR as of Q1 2016.

Sphera Funds Management reported no remaining aTyr Pharma position as of Q1 2016 after selling out during the quarter.
Sphera Funds Management sold 2,604 aTyr Pharma shares in Q1 2016, an estimated $358K.
Sphera Funds Management first reported a position in aTyr Pharma in Q2 2015 and held it in 3 quarters.
Sphera Funds Management's aTyr Pharma position peaked at $3.7M in Q2 2015.
50 funds tracked by Wall St. Rank held aTyr Pharma as of Q1 2016.

Based on Sphera Funds Management's 13F filing for Q1 2016, filed 16 May 2016.